Use of IP chemotherapy in ovarian cancer: the critical questions.

摘要

The article by Dr. Echarri Gonzalez and her colleagues regarding intraperitoneal (IP) chemotherapy for women with epithelial ovarian cancer provides a comprehensive yet practical'review of the critical questions surrounding the use of IP chemotherapy. As the authors note, on the basis of eight randomized, phase III trials, the US National Cancer Institute (NCI) issued a Clinical Announcement in 2006 recommending a combination of IP and intravenous (IV) chemotherapy including platins and taxanes for women with stage III ovarian cancer who have minimal residual disease after primary debulking surgery. For purposes of full disclosure, all the authors of this commentary concur with the NCI Clinical Announcement.Critical to optimal care of women with advanced ovarian cancer is the need for the combination of effective surgical debulking and chemotherapy.